US equities |
NVDA $236.40 ▲+1.05% MU $1,066.28 ▼-0.80% INTC $116.05 ▼-2.75% MSFT $526.52 ▲+1.74% AMD $626.50 ▼-1.17% SPCX $160.39 ▲+0.90% TSLA $365.10 ▼-1.48% META $732.77 ▲+0.64%
FinancialContent

Prime Medicine, Inc. - Common Stock (NQ:PRME)

2.940 -0.040 (-1.34%)
Delayed Quote Updated: 9:33 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prime Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine (NASDAQ:PRME) Q1 Results Show Revenue Miss and Narrower Loss as Key Pipeline Milestones Loom ↗
Via Chartmill
News headline image
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? ↗
Two biotech innovators, two very different risk profiles: one with commercial products and another betting on next-gen gene editing breakthroughs. 
Via The Motley Fool
News headline image
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at Jefferies Global Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at Jefferies Global Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy
-- Webcast event to begin at 8:00am ET on Wednesday, November 12, 2025 -- 
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue. 
Via Benzinga
News headline image
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >